



PTO/SB/08A/B (09-06)

Approved for use through 03/31/2007. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|---|---|----|---|--------------------------|---------------------------|
| Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i> | | | | Complete if Known | |
| | | | | Application Number | 10/583,280 – Conf. # 2639 |
| | | | | Filing Date | June 16, 2006 |
| | | | | First Named Inventor | Charles Sawyers |
| | | | | Art Unit | 1636 |
| | | | | Examiner Name | Nancy S. Vogel |
| Sheet | 1 | of | 7 | Attorney Docket Number | 58086-232451 |

| U.S. PATENT DOCUMENTS | | | | | |
|-----------------------|--------------------------|--|--------------------------------|--|---|
| Examiner Initials* | Cite No. ¹ | Document Number | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
| | | Number-Kind Code ² (if known) | | | |
| | A1 | 4,097,578 | 06-27-1978 | Perronnet et al. | |
| | A2 | 4,399,216 | 08-16-1983 | Axel et al. | |
| | A3 | 4,559,157 | 12-17-1985 | Smith et al. | |
| | A4 | 4,608,392 | 08-26-1986 | Jacquet et al. | |
| | A5 | 4,820,508 | 04-11-1989 | Wortzman | |
| | A6 | 4,938,949 | 07-03-1990 | Borch et al. | |
| | A7 | 4,992,478 | 02-12-1991 | Geria | |
| | A8 | 5,010,182 | 04-23-1991 | Brake et al. | |
| | A9 | 5,411,981 | 05-02-1995 | Gaillard-Kelly et al. | |
| | A10 | 5,434,176 | 07-18-1995 | Claussner et al. | |
| | A11 | 5,656,651 | 08-12-1997 | Sovak et al. | |
| | A12 | 5,705,654 | 01-06-1998 | Claussner et al. | |
| | A13 | 5,750,553 | 05-12-1998 | Claussner et al. | |
| | A14 | 5,985,868 | 11-16-1999 | Gray | |
| | A15 | 6,087,509 | 07-11-2000 | Claussner et al. | |
| | A16 | 6,479,063 | 11-12-2002 | Weisman et al. | |
| | A17 | 6,506,607 | 01-14-2003 | Shyjan | |
| | A18 | 2004/0009969 | 01-15-2004 | Cleve et al. | |
| | A19 | 2002/0133833 A1 | 09-19-2002 | Sawyers et al. | |
| | A20 | 6,828,471 | 12-07-04 | Sawyers et al. | |

| | | | |
|-----------------------|--|--------------------|--|
| Examiner Signature | | Date Considered | |
|-----------------------|--|--------------------|--|

| | | | | | |
|--|---|----|---|--------------------------|---------------------------|
| Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i> | | | | Complete if Known | |
| | | | | Application Number | 10/583,280 – Conf. # 2639 |
| | | | | Filing Date | June 16, 2006 |
| | | | | First Named Inventor | Charles Sawyers |
| | | | | Art Unit | 1636 |
| | | | | Examiner Name | Nancy S. Vogel |
| Sheet | 2 | of | 7 | Attorney Docket Number | 58086-232451 |

| FOREIGN PATENT DOCUMENTS | | | | | | |
|--------------------------|--------------------------|--|-----------------------------------|--|--|----------------|
| Examiner Initials* | Cite No. ¹ | Foreign Patent Document | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T ⁶ |
| | | Country Code ³ -Number ⁴ -Kind Code ⁵ (if known) | | | | |
| | B1 | EP 362,179 | 04-04-1990 | Smithkline Beecham Corporation | | |
| | B2 | WO 00/17163 (with English abstract) | 03-30-2000 | Yamanouchi Pharmaceutical Co., Ltd., et al. | | |
| | B3 | WO 90/13646 (with English abstract) | 11-15-1990 | Transgene S.A. Achstetter, et al. | | |
| | B4 | WO 97/00071 | 01-03-1997 | Biophysica Foundation Sovak, et al. | | |
| | B5 | WO 2005/099693 | 10-27-2005 | The Regents of the University of California | | |
| | B6 | WO 2006/124118 | 11-23-2006 | The Regents of the University of California | | |
| | B7 | WO 2005/059109 | 06-30-2005 | The Regents of the University of California | | |

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

| NON PATENT LITERATURE DOCUMENTS | | | | | | |
|---------------------------------|--------------------------|--|--|--------------------|--|----------------|
| Examiner Initials | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | | | | T ² |
| | | | | | | |
| | C1 | Karp et al., Cancer Res. 56: 5547-5556. | | | | |
| | C2 | Ausubel et al., Current Protocols in Molecular Biology, Wiley Interscience Publishers, (1995). | | | | |
| | C3 | Sambrook et al., Molecular Cloning: A Laboratory Manual 2 nd edition (1989) Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. | | | | |
| | C4 | Chang et al., Science 240 (4850), 324-326 (1988). | | | | |
| | C5 | NM_000044< http://www.ncbi.nlm.nih.gov:80/entrez/viewer.fcgi?cmd=Retrieve&db=nucleotide&list_uids=21322251&dopt=GenBank&term=sapiens+AR+androgen+recept or+prostate+cancer&qty=1 >gi:21322251, printed October 24, 2007. | | | | |
| | C6 | Mammalian Cell Biotechnology: a Practical Approach, M. Butler, ed. (IRL Press, 1991). | | | | |
| | C7 | Graham and van der Eb, Virology, 52:456-467. | | | | |
| | C8 | Keown et al., Methods in Enzymology, 185:527-537 (1990). | | | | |
| | C9 | Mansour et al., Nature, 336:348-352 (1988). | | | | |
| | C10 | Muller et al., 1991, Mol. & Cell. Bio. 11:1785. | | | | |
| | C11 | Urlaub et al., Proc. Natl. Acad. Sci. USA, 77:4216 (1980). | | | | |
| | C12 | Stinchcomb et al., Nature, 282:39 (1979). | | | | |
| Examiner Signature | | | | Date Considered | | |

| | | | | | |
|--|---|----|---|--------------------------|---------------------------|
| Substitute for form 1449/PTO | | | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i> | | | | Application Number | 10/583,280 – Conf. # 2639 |
| | | | | Filing Date | June 16, 2006 |
| | | | | First Named Inventor | Charles Sawyers |
| | | | | Art Unit | 1636 |
| | | | | Examiner Name | Nancy S. Vogel |
| Sheet | 3 | of | 7 | Attorney Docket Number | 58086-232451 |

| | | |
|-----|--|--|
| C13 | Kingsman et al., <u>Gene</u> , 7: 141 (1979). | |
| C14 | Tschumper et al., <u>Gene</u> , 10: 157 (1980). | |
| C15 | Jones, <u>Genetics</u> , 85:12 (1977). | |
| C16 | Feldman, B.J. & Feldman, D. The development of androgen-independent prostate cancer. <u>Nat Rev Cancer</u> 1, 34-45 (2001). | |
| C17 | Gelmann, E.P. Molecular biology of the androgen receptor. <u>J Clin Oncol</u> 20, 3001-15 (2002). | |
| C18 | Balk, S.P. Androgen receptor as a target in androgen-independent prostate cancer. <u>Urology</u> 60, 132-8; discussion 138-9 (2002). | |
| C19 | Taplin, M.E. et al. Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist. <u>Cancer Res</u> 59, 2511-5 (1999). | |
| C20 | Taplin, M.E. et al. Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663. <u>J Clin Oncol</u> 21, 2673-8 (2003). | |
| C21 | Visakorpi, T. et al. In vivo amplification of the androgen receptor gene and progression of human prostate cancer. <u>Nat Genet</u> 9, 401-6 (1995). | |
| C22 | Taplin, M.E. et al. Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. <u>N Engl J Med</u> 332, 1393-8 (1995). | |
| C23 | Veldscholte, J. et al. A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. <u>Biochem Biophys Res Commun</u> 173, 534-40 (1990). | |
| C24 | Matias, P.M. et al. Structural basis for the glucocorticoid response in a mutant human androgen receptor (AR(ccr)) derived from an androgen-independent prostate cancer. <u>J Med Chem</u> 45, 1439-46 (2002). | |
| C25 | Craft, N., Shostak, Y., Carey, M. & Sawyers, C.L. A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. <u>Nat Med</u> 5, 280-5 (1999). | |
| C26 | Gioeli, D. et al. Androgen receptor phosphorylation. Regulation and identification of the phosphorylation sites. <u>J Biol Chem</u> 277, 29304-14 (2002). | |
| C27 | Kato, S. et al. Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. <u>Science</u> 270, 1491-4 (1995). | |
| C28 | Font de Mora, J. & Brown, M. AIB1 is a conduit for kinase-mediated growth factor signaling to the estrogen receptor. <u>Mol Cell Biol</u> 20, 5041-7 (2000). | |
| C29 | Tremblay, A., Tremblay, G.B., Labrie, F. & Giguere, V. Ligand-independent recruitment of SRC-1 to estrogen receptor beta through phosphorylation of activation function AF-1. <u>Mol Cell</u> 3, 513-9 (1999). | |
| C30 | Gregory, C.W. et al. A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy. <u>Cancer Res</u> 61, 4315-9 (2001). | |
| C31 | Li, P. et al. Heterogeneous expression and functions of androgen receptor co-factors in primary prostate cancer. <u>Am J Pathol</u> 161, 1467-74 (2002). | |
| C32 | Glass, C.K. & Rosenfeld, M.G. The coregulator exchange in transcriptional functions of nuclear receptors. <u>Genes Dev</u> 14, 121-41 (2000). | |

| | | | |
|--------------------|--|-----------------|--|
| Examiner Signature | | Date Considered | |
|--------------------|--|-----------------|--|

| | | | | | |
|--|---|----|---|--------------------------|---------------------------|
| Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i> | | | | Complete if Known | |
| | | | | Application Number | 10/583,280 – Conf. # 2639 |
| | | | | Filing Date | June 16, 2006 |
| | | | | First Named Inventor | Charles Sawyers |
| | | | | Art Unit | 1636 |
| | | | | Examiner Name | Nancy S. Vogel |
| Sheet | 4 | of | 7 | Attorney Docket Number | 58086-232451 |

| | | |
|-----|---|--|
| C33 | Raffo, A.J. et al. Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo. Cancer Res 55, 4438-45 (1995). | |
| C34 | McDonnell, T.J. et al. Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res 52, 6940-4 (1992). | |
| C35 | Kinoshita, H. et al. Methylation of the androgen receptor minimal promoter silences transcription in human prostate cancer. Cancer Res 60, 3623-30 (2000). | |
| C36 | Shang, Y., Myers, M. & Brown, M. Formation of the androgen receptor transcription complex. Mol Cell 9, 601-10 (2002). | |
| C37 | Zhau, H.Y. et al. Androgen-repressed phenotype in human prostate cancer. Proc Natl Acad Sci U S A 93, 15152-7 (1996). | |
| C38 | Wainstein, M.A. et al. CWR22: androgen-dependent xenograft model derived from a primary human prostatic carcinoma. Cancer Res 54, 6049-52 (1994). | |
| C39 | Ellis, W.J. et al. Characterization of a novel androgen-sensitive, prostate-specific antigen-producing prostatic carcinoma xenograft: LuCaP 23. Clin Cancer Res 2, 1039-48 (1996). | |
| C40 | Horoszewicz, J.S. et al. LNCaP model of human prostatic carcinoma. Cancer Res 43, 1809-18 (1983). | |
| C41 | Klein, K.A. et al. Progression of metastatic human prostate cancer to androgen independence in immunodeficient SCID mice. Nat Med 3, 402-8 (1997). | |
| C42 | Perou, C.M. et al. Molecular portraits of human breast tumors. Nature 406, 747-52 (2000). | |
| C43 | Gregory, C.W., Johnson, R.T., Jr., Mohler, J.L., French, F.S. & Wilson, E.M. Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen. Cancer Res 61, 2892-8. (2001). | |
| C44 | Huang, Z.Q., Li, J. & Wong, J. AR possess an intrinsic hormone-independent transcriptional activity. Mol Endocrinol 16, 924-37 (2002). | |
| C45 | Matias, P.M. et al. Structural evidence for ligand specificity in the binding domain of the human androgen receptor. Implications for pathogenic gene mutations. J Biol Chem 275, 26164-71 (2000). | |
| C46 | Lobaccaro, J.M. et al. Molecular modeling and in vitro investigations of the human androgen receptor DNA-binding domain: application for the study of two mutations. Mol Cell Endocrinol 116, 137-47 (1996). | |
| C47 | Migliaccio, A. et al. Steroid-induced androgen receptor-oestradiol receptor beta-Src complex triggers prostate cancer cell proliferation. Embo J 19, 5406-17 (2000). | |
| C48 | Kousteni, S. et al. Nongenotropic, sex-nonspecific signaling through the estrogen or androgen receptors: dissociation from transcriptional activity. Cell 104, 719-30 (2001). | |
| C49 | Manolagas, S.C., Kousteni, S. & Jilka, R.L. Sex steroids and bone. Recent Prog Horm Res 57, 385-409 (2002). | |

| | | | |
|--------------------|--|-----------------|--|
| Examiner Signature | | Date Considered | |
|--------------------|--|-----------------|--|

| | | | | | |
|--|---|----|---|--------------------------|---------------------------|
| Substitute for form 1449/PTO | | | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i> | | | | Application Number | 10/583,280 – Conf. # 2639 |
| | | | | Filing Date | June 16, 2006 |
| | | | | First Named Inventor | Charles Sawyers |
| | | | | Art Unit | 1636 |
| | | | | Examiner Name | Nancy S. Vogel |
| Sheet | 5 | of | 7 | Attorney Docket Number | 58086-232451 |

| | | |
|-----|--|--|
| C50 | DePrimo, S.E. et al. Transcriptional programs activated by exposure of human prostate cancer cells to androgen. <i>Genome Biol</i> 3, RESEARCH0032 (2002). | |
| C51 | Masiello, D., Cheng, S., Bubley, G.J., Lu, M.L. & Balk, S.P. Bicalutamide functions as an androgen receptor antagonist by assembly of a transcriptionally inactive receptor. <i>J Biol Chem</i> 277, 26321-6 (2002). | |
| C52 | Edwards, J., Krishna, N.S., Grigor, K.M. & Bartlett, J.M. Androgen receptor gene amplification and protein expression in hormone refractory prostate cancer. <i>Br J Cancer</i> 89, 552-6 (2003). | |
| C53 | Laitinen, S., Karhu, R., Sawyers, C.L., Vessella, R.L. & Visakorpi, T. Chromosomal aberrations in prostate cancer xenografts detected by comparative genomic hybridization. <i>Genes Chromosomes Cancer</i> 35, 66-73 (2002). | |
| C54 | Grad, J.M., Dai, J.L., Wu, S. & Burnstein, K.L. Multiple androgen response elements and a Myc consensus site in the androgen receptor (AR) coding region are involved in androgen-mediated up-regulation of AR messenger RNA. <i>Mol Endocrinol</i> 13, 1896-911 (1999). | |
| C55 | Craft, N. et al. Evidence for clonal outgrowth of androgen-independent prostate cancer cells from androgen-dependent tumors through a two-step process. <i>Cancer Res</i> 59,5030-6 (1999). | |
| C56 | Ellwood-Yen, K. et al. Myc-driven murine prostate cancer shares molecular features with human prostate tumors. <i>Cancer Cell</i> 4, 223-38 (2003). | |
| C57 | Wang, S. et al. Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. <i>Cancer Cell</i> 4, 209-21 (2003). | |
| C58 | Shiau, A.K. et al. The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. <i>Cell</i> 95, 927-37 (1998). | |
| C59 | Norris, J.D. et al. Peptide antagonists of the human estrogen receptor. <i>Science</i> 285, 744-6 (1999). | |
| C60 | Baek, S.H. et al. Exchange of N-CoR corepressor and Tip60 coactivator complexes links gene expression by NF-kappaB and beta-amyloid precursor protein. <i>Cell</i> 110, 55-67 (2002). | |
| C61 | Shang, Y. & Brown, M. Molecular determinants for the tissue specificity of SERMs. <i>Science</i> 295, 2465-8 (2002). | |
| C62 | Schellhammer, P.F. et al. Prostate specific antigen decreases after withdrawal of antiandrogen therapy with bicalutamide or flutamide in patients receiving combined androgen blockade. <i>J Urol</i> 157, 1731-5 (1997). | |
| C63 | Sack, J.S. et al. Crystallographic structures of the ligand-binding domains of the androgen receptor and its T877A mutant complexed with the natural agonist dihydrotestosterone. <i>Proc Natl Acad Sci U S A</i> 98, 4904-9 (2001). | |
| C64 | Zhou, Z.X., Sar, M., Simental, J.A., Lane, M.V. & Wilson, E.M. A ligand-dependent bipartite nuclear targeting signal in the human androgen receptor. Requirement for the DNA-binding domain and modulation by NH2-terminal and carboxyl-terminal sequences. <i>J Biol Chem</i> 269, 13115-23 (1994). | |

| | | | |
|--------------------|--|-----------------|--|
| Examiner Signature | | Date Considered | |
|--------------------|--|-----------------|--|

| | | | | | |
|--|---|----|---|--------------------------|---------------------------|
| Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i> | | | | Complete if Known | |
| | | | | Application Number | 10/583,280 – Conf. # 2639 |
| | | | | Filing Date | June 16, 2006 |
| | | | | First Named Inventor | Charles Sawyers |
| | | | | Art Unit | 1636 |
| | | | | Examiner Name | Nancy S. Vogel |
| Sheet | 6 | of | 7 | Attorney Docket Number | 58086-232451 |

| | | |
|-----|--|--|
| C65 | Chen, C.D., Welsbie, D.S., Tran, C., Baek, S.H., Chen, R., Vessella, R., Rosenfeld, M.G., and Sawyers, C.L., Molecular determinants of resistance to antiandrogen therapy, <i>Nat. Med.</i> , 10: 33-39, 2004. | |
| C66 | <i>The Pharmacological Basis of Therapeutics</i> , Goodman and Gilman, eds., Macmillan Publishing Co., New York. | |
| C67 | The Practice of Medicinal Chemistry, Camille G. Wermuth et al., Ch 31, (Academic Press, 1996). | |
| C68 | Design of Prodrugs, edited by H. Bundgaard, (Elsevier, 1985). | |
| C69 | A Textbook of Drug Design and Development, P. Krogsgaard-Larson and H. Bundgaard, eds. Ch 5, pgs 113-191 (Harwood Academic Publishers, 1991). | |
| C70 | Remington: The Science and Practice of Pharmacy, 19 th Edition, Gennaro (ed.) 1995, Mack Publishing Company, Easton, PA. | |
| C71 | Teutsch, G.; Goubet, F.; Battmann, T.; Bonfils, A.; Bouchoux, F.; Cerede, E.; Gofflo, D.; Gaillard-Kelly, M.; Philibert, D. <i>J. Steroid Biochem. Molec. Biol.</i> 1994 , <i>48</i> , 111-119. | |
| C72 | Van Dort, M. E.; Robins, D. M.; Wayburn, B. <i>J. Med. Chem.</i> 2000 , <i>43</i> , 3344-3347. | |
| C73 | Homma, S., et al., "Differential levels of human leukocyte antigen-class I, multidrug-resistance 1 and androgen receptor expressions in untreated prostate cancer cells: the robustness of prostate cancer", <i>Oncol. Rep.</i> 18 (2), 343-346 (2007). | |
| C74 | Cai, C., et al., "c-Jun has multiple enhancing activities in the novel cross talk between the androgen receptor and Ets variant gene 1 in prostate cancer", <i>Mol. Cancer Res.</i> 5 (7), 725-735 (2007). | |
| C75 | Su, Q.R., et al., "Polymorphisms of androgen receptor gene in childhood and adolescent males with first-onset major depressive disorder and association with related symptomatology", <i>Int. J. Neurosci.</i> 117 (7), 903-917 (2007). | |
| C76 | Brockschmidt, F.F., et al., "The two most common alleles of the coding GGN repeat in the androgen receptor gene cause differences in protein function", <i>J. Mol. Endocrinol.</i> 39 (1), 1-8 (2007). | |
| C77 | Hamilton-Reeves, J.M., et al., "Isoflavone-rich soy protein isolate suppresses androgen receptor expression without altering estrogen receptor-beta expression or serum hormonal profiles in men at high risk of prostate cancer", <i>J. Nutr.</i> 137 (7), 1769-1775 (2007). | |
| C78 | Sweet, C.R., et al., "A unique point mutation in the androgen receptor gene in a family with complete androgen insensitivity syndrome", <i>Fertil. Steril.</i> 58 (4), 703-707 (1992). | |
| C79 | Batch, J.A., et al., "Androgen receptor gene mutations identified by SSCP in fourteen subjects with androgen insensitivity syndrome", <i>Hum. Mol. Genet.</i> 1 (7), 497-503 (1992). | |
| C80 | Wooster, R., et al., "A germline mutation in the androgen receptor gene in two brothers with breast cancer and Reifenstein syndrome", <i>Nat. Genet.</i> 2 (2), 132-134 (1992). | |

| | | | |
|--------------------|--|-----------------|--|
| Examiner Signature | | Date Considered | |
|--------------------|--|-----------------|--|

| | | | | | |
|--|---|----|---|--------------------------|---------------------------|
| Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i> | | | | Complete if Known | |
| | | | | Application Number | 10/583,280 – Conf. # 2639 |
| | | | | Filing Date | June 16, 2006 |
| | | | | First Named Inventor | Charles Sawyers |
| | | | | Art Unit | 1636 |
| | | | | Examiner Name | Nancy S. Vogel |
| Sheet | 7 | of | 7 | Attorney Docket Number | 58086-232451 |

| | | | |
|--|-----|--|--|
| | C81 | Saunders, P.T., et al., "Point mutations detected in the androgen receptor gene of three men with partial androgen insensitivity syndrome", Clin. Endocrinol. (Oxf) 37 (3), 214-220 (1992). | |
| | C82 | Zoppi, S., et al. " Amino acid substitutions in the DNA-binding domain of the human androgen receptor are a frequent cause of receptor-binding positive androgen resistance", Mol. Endocrinol. 6 (3), 409-415 (1992). | |
| | C83 | International Search Report issued in PCT Application PCT/US2006/011417, mailed on July 3, 2006. | |
| | C84 | International Search Report issued in PCT Application PCT/US2005/005529, mailed on November 10, 2005. | |
| | C85 | International Search Report issued in PCT Application PCT/US2004/042221, mailed on June 20, 2005. | |
| | C86 | Wang, Long G., et al., "Overexpressed androgen receptor linked to p21WAF1 silencing may be responsible for androgen independence and resistance to apoptosis of a prostate cancer cell line", Cancer Research 61 (20), pp. 7544-7551 (October 15, 2001). | |
| | C87 | Shi, Xu-Bao, et al., "Functional analysis of 44 mutant androgen receptors from human prostate cancer", Cancer Research 62 (5), pp. 1496-1502 (March 1, 2002). | |
| | C88 | Navone, N. M., et al., "Model Systems of Prostate Cancer: Uses and Limitations" Cancer Metastasis, Kluwer Academic Publishers, Dordrecht, NL, 17 (4), 1999, pp. 361-371. | |

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

| | | | |
|-----------------------|--|--------------------|--|
| Examiner Signature | | Date Considered | |
|-----------------------|--|--------------------|--|